Literature DB >> 11115831

Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development.

L Benvegnù1, F Noventa, E Bernardinello, P Pontisso, A Gatta, A Alberti.   

Abstract

BACKGROUND: Patients with liver cirrhosis are at significant risk of hepatocellular carcinoma (HCC) that may develop as well defined nodular lesions or as more aggressive infiltrating tumours. AIM: To compare prospectively risk factors associated with nodular or infiltrating HCC in cirrhotic patients. PATIENTS AND METHODS: We studied 370 patients with cirrhosis, followed prospectively by periodic ultrasound (US) of the liver, for a mean period of 74.6 (SD 32.4) months to define the incidence and patterns of HCC development. Patients who developed HCC were compared according to tumour pattern using univariate and multivariate analysis.
RESULTS: Sixty one (16.5%) patients developed HCC: HCC was classified as nodular in 49 (80.3%) and infiltrating in 12 (19.7%) according to US and computerised tomography (CT) imaging. The five and 10 year cumulative probabilities were 8.1% (95% confidence interval (CI) 5. 2%-11%) and 25.2% (15.0-35.4%) for nodular HCC and 2.1% (0.5-3.7%) and 6.9% (2.1-11.7%) for infiltrating HCC. Patients with infiltrating HCC were younger than those with nodular HCC (59.5 v 66. 2 years, 95% CI 55.2-63.8 and 64.1-68.3 years; p=0.014). Using multivariate analysis, development of nodular HCC was associated with older age (p=0.0002; relative risk (RR) 3.1; 95% CI 1.6-5.2), longer duration (p=0.09; RR 2.6; 95% CI 1.8-3.4), and more advanced stage (p=0.002; RR 2.5; 95% CI 1.3-4.5) of cirrhosis but not with the aetiology of liver disease. In contrast, development of infiltrating HCC appeared to be unrelated to age or disease duration or stage, while it was associated with hepatitis B virus infection (p=0.07; RR 3.96; 95% CI 1.1-5.2) and with hepatitis B/hepatitis C virus coinfection (p=0.0007; RR 16.9; 95% CI 3.8-36.7).
CONCLUSIONS: In liver cirrhosis, we identified two patterns of HCC developing with distinct risk factors. Nodular HCC was related to the cirrhotic process per se independent of aetiological factors and may depend on the proliferative activity within regenerative nodules, while the infiltrating form of HCC was linked to hepatitis B virus infection and may reflect more direct virus induced carcinogenesis.

Entities:  

Mesh:

Year:  2001        PMID: 11115831      PMCID: PMC1728185          DOI: 10.1136/gut.48.1.110

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  30 in total

1.  Ultrasonography-detected macroregenerative nodules in cirrhosis: a prospective study.

Authors:  M Borzio; F Borzio; A Croce; M Sala; A Salmi; G Leandro; S Bruno; M Roncalli
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

Review 2.  Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association.

Authors:  W Szmuness
Journal:  Prog Med Virol       Date:  1978

3.  Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study.

Authors:  J C Sheu; J L Sung; D S Chen; M Y Lai; T H Wang; J Y Yu; P M Yang; C N Chuang; P C Yang; C S Lee
Journal:  Cancer       Date:  1985-08-01       Impact factor: 6.860

4.  Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study.

Authors:  M Borzio; S Bruno; M Roncalli; G C Mels; G Ramella; F Borzio; G Leandro; E Servida; M Podda
Journal:  Gastroenterology       Date:  1995-03       Impact factor: 22.682

5.  Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients.

Authors:  S N Zaman; W M Melia; R D Johnson; B C Portmann; P J Johnson; R Williams
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

6.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

7.  Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma.

Authors:  C Brechot; C Pourcel; A Louise; B Rain; P Tiollais
Journal:  Nature       Date:  1980-07-31       Impact factor: 49.962

8.  Hepatocellular carcinoma in Italian patients with cirrhosis.

Authors:  M Colombo; R de Franchis; E Del Ninno; A Sangiovanni; C De Fazio; M Tommasini; M F Donato; A Piva; V Di Carlo; N Dioguardi
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

9.  Hepatitis B virus infection in southern African blacks with hepatocellular cancer.

Authors:  M C Kew; J Desmyter; A F Bradburne; G M Macnab
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

10.  Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein.

Authors:  M Cottone; M Turri; M Caltagirone; P Parisi; A Orlando; G Fiorentino; R Virdone; G Fusco; R Grasso; R G Simonetti
Journal:  J Hepatol       Date:  1994-12       Impact factor: 25.083

View more
  26 in total

Review 1.  Infiltrating hepatocellular carcinoma: seeing the tree through the forest.

Authors:  Aram Demirjian; Peter Peng; Jean-Francois H Geschwind; David Cosgrove; Jacob Schutz; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2011-07-02       Impact factor: 3.452

Review 2.  Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease.

Authors:  Pierre Nahon; Angela Sutton; Marianne Ziol; Jessica Zucman-Rossi; Jean-Claude Trinchet; Nathalie Ganne-Carrié
Journal:  Hepat Oncol       Date:  2015-01-12

3.  Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes.

Authors:  Peter J Kneuertz; Aram Demirjian; Amin Firoozmand; Celia Corona-Villalobos; Nikhil Bhagat; Joseph Herman; Andrew Cameron; Ahmet Gurakar; David Cosgrove; Michael A Choti; Jean-Francois H Geschwind; Ihab R Kamel; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2012-04-03       Impact factor: 5.344

Review 4.  Surveillance for hepatocellular carcinoma.

Authors:  Jeyamani Ramachandran
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

Review 5.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.

Authors:  Mindie H Nguyen; Grace Wong; Edward Gane; Jia-Horng Kao; Geoffrey Dusheiko
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

Review 6.  Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

Authors:  E B Melian; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

8.  Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma.

Authors:  Neil Mehta; Nicholas Fidelman; Monika Sarkar; Francis Y Yao
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

9.  Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization.

Authors:  Eun Sun Jang; Jung-Hwan Yoon; Jin Wook Chung; Eun Ju Cho; Su Jong Yu; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-03       Impact factor: 4.553

Review 10.  Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments.

Authors:  Xavier Adhoute; Guillaume Penaranda; Jean Luc Raoul; Patrice Le Treut; Emilie Bollon; Jean Hardwigsen; Paul Castellani; Hervé Perrier; Marc Bourlière
Journal:  World J Hepatol       Date:  2016-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.